secretion associated Ras related GTPase 1AGenealiases: SAR1 · SARA1 · Sara · masra2
Q-omics provides the consensus-scored SAR1A profile across patient tissues and cancer cell-line models. SAR1A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SAR1A is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, SAR1A protein abundance shows 20,302 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight HNSC as cancer lineages where SAR1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SAR1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SAR1A survival associations across molecular data types. SAR1A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SAR1A RNA expression–survival associations across cancer types. High SAR1A expression shows unfavorable associations in HNSC, ACC, BLCA, UVM and LIHC, but favorable associations in LGG. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SAR1A RNA expression.
This table summarizes SAR1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SAR1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SAR1A shows lower tumor expression in THCA, LUAD, KICH and LUSC and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher SAR1A RNA expression in tumor versus normal tissue (log2 FC = +0.801, t-test p < 0.001).
This table shows molecular features associated with SAR1A in patient tissues and cancer cell lines. In patient samples, SAR1A shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SAR1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
